21 September 2020

Amedeo Smart

Independent Medical Education


Subscriber: th..@boehringer-ingelheim.com

HIV Infection

21 September 2020 | n=38

  1. Muccini C, Spagnuolo V, Canetti D, Bigoloni A, et al.
    CSF viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance.
    AIDS 2020.

  2. Wilson IB, Tie Y, Padilla M, Rogers WH, et al.
    Performance of a short, self-report adherence scale in a probability sample of persons using HIV antiretroviral therapy in the United States.
    AIDS 2020.

  3. Bouvin-Pley M, Leoz M, Roch E, Moreau A, et al.
    Differential utilization of CD4 by transmitted/founder and chronic envelope glycoproteins in a MSM HIV-1 subtype B transmission cluster.
    AIDS 2020.

  4. Moyo T, Guleid FH, Schomaker M, Williamson C, et al.
    HIV-1 Subtype C tier 3 viruses have increased infectivity as compared to tier 2 viruses.
    AIDS Res Hum Retroviruses 2020.

  5. Koofhethile CK, Moyo S, Kotokwe KP, Chang CA, et al.
    Detection of inducible replication-competent HIV-1C provirus despite long-term antiretroviral treatment in perinatally infected adolescents in Botswana.
    AIDS Res Hum Retroviruses 2020.

  6. Calza L, Borderi M, Colangeli V, Esposito F, et al.
    NO SIGNIFICANT INCREASE IN BODY FAT MASS IN NAIVE HIV-INFECTED PATIENTS STARTING RALTEGRAVIR PLUS TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE.
    AIDS Res Hum Retroviruses 2020.

  7. Das M, Ting J, Shreay S, Bush S, et al.
    Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
    Ann Intern Med 2020;173:506-507.

  8. Walensky RP, Horn T, McCann NC, Freedberg KA, et al.
    Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
    Ann Intern Med 2020;173:507-508.

  9. Rebeiro PF, Jenkins CA, Bian A, Lake JE, et al.
    Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada.
    Clin Infect Dis 2020.

  10. Frascella B, Richards AS, Sossen B, Emery JC, et al.
    Subclinical tuberculosis disease - a review and analysis of prevalence surveys to inform definitions, burden, associations and screening methodology.
    Clin Infect Dis 2020.

  11. Carrero A, Berenguer J, Hontanon V, Guardiola JM, et al.
    Effects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patients.
    Clin Infect Dis 2020.

  12. Dookie N, Padayatchi N, Naidoo K.
    Tuberculosis Elimination in the Era of COVID-19: A Moving Target.
    Clin Infect Dis 2020.

  13. Hellmuth J, Muccini C, Colby DJ, Kroon E, et al.
    Central nervous system safety during brief analytic treatment interruption of antiretroviral therapy within four HIV remission trials: an observational study in acutely treated people living with HIV.
    Clin Infect Dis 2020.

  14. Gindin Y, Gaggar A, Lok AS, Janssen HLA, et al.
    DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV or HCV, with or without HIV Co-Infection.
    Clin Infect Dis 2020.

  15. Anderson AM, Jang JH, Easley KA, Fuchs D, et al.
    Cognitive and neuronal link with inflammation: a longitudinal study in people with and without HIV infection.
    J Acquir Immune Defic Syndr 2020.

  16. Mugo C, Wang J, Begnel ER, Njuguna IN, et al.
    Home- and clinic-based pediatric HIV index case testing in Kenya: Uptake, HIV prevalence, linkage to care, and missed opportunities.
    J Acquir Immune Defic Syndr 2020.

  17. Jimenez-Sousa MA, Jimenez JL, Bellon JM, Fernandez-Rodriguez A, et al.
    CYP27B1 rs10877012 T allele was linked to non-AIDS progression in ART-naive HIV-infected patients: a retrospective study.
    J Acquir Immune Defic Syndr 2020.

  18. Raju S, McCormack MC, Drummond MB, Ramamurthi HC, et al.
    Association of Lung Function With HIV-Related Quality of Life and Health Care Utilization in a High-Risk Cohort.
    J Acquir Immune Defic Syndr 2020;85:219-226.

  19. MacCarthy S, Wagner Z, Barreras JL, Kim A, et al.
    Brief Report: Using Behavioral Economics to Increase HIV Knowledge and Testing Among Latinx Sexual Minority Men and Transgender Women: A Quasi-Experimental Pilot Study.
    J Acquir Immune Defic Syndr 2020;85:189-194.

  20. Boettiger DC, Kerr S, Chattranukulchai P, Siwamogsatham S, et al.
    Reclassification of Statin Indication Among People Living With HIV Using Coronary Artery Calcium Scoring.
    J Acquir Immune Defic Syndr 2020;85:e26-e29.

  21. Surial B, Beguelin C, Chave JP, Stockle M, et al.
    Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    J Acquir Immune Defic Syndr 2020;85:227-232.

  22. Yanuar Safri A, Gaff J, Octaviana F, Dewanto Setiawan D, et al.
    Demographic and genetic associations with markers of small and large fibre sensory neuropathy in HIV patients treated without stavudine.
    J Acquir Immune Defic Syndr 2020.

  23. Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, et al.
    An evaluation of 6-month versus continuous isoniazid preventive therapy for M. tuberculosis in adults living with HIV/AIDS in Malawi.
    J Acquir Immune Defic Syndr 2020.

  24. Clarke DF, Lommerse J, Acosta EP, Cababasay MP, et al.
    IMPACT OF LOW BIRTH WEIGHT AND PREMATURITY ON NEONATAL RALTEGRAVIR PHARMACOKINETICS: IMPAACT P1097.
    J Acquir Immune Defic Syndr 2020.

  25. Spring S, O'Bryan J, McMahon J, Woolley I, et al.
    Acceptability of injectable anti-retroviral therapy in Australian travellers with HIV.
    J Acquir Immune Defic Syndr 2020.

  26. Martin EA, Lai MT, Ngo W, Feng M, et al.
    Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
    J Acquir Immune Defic Syndr 2020.

  27. Gatechompol S, Teeratakulpisarn N, Wittawatmongkol O, Teeraananchai S, et al.
    Incidence, persistence, and factors associated with HPV infection among male adolescents with and without perinatally acquired HIV infection.
    J Acquir Immune Defic Syndr 2020.

  28. McCree DH, Chesson HW, Eppink ST, Beer L, et al.
    Changes in Racial and Ethnic Disparities in Estimated Diagnosis Rates of Heterosexually-acquired HIV Infection among Heterosexual Males in the United States, 2014-2018.
    J Acquir Immune Defic Syndr 2020.

  29. Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, et al.
    Some But Not All Biomarkers of Immune Activation Remain Abnormal Despite Very Early Treatment of HIV.
    J Infect Dis 2020.

  30. da Silva DM, Goncales JP, Silva Junior JVJ, Lopes TRR, et al.
    Evaluation of IL-2, IL-4, IL-6, IL-10, TNF-alpha and IFN-gamma cytokines in HIV/HHV-8 coinfection.
    J Med Virol 2020.

  31. Fernandez MV, Hoffman HK, Pezeshkian N, Tedbury PR, et al.
    Elucidating the basis for permissivity of the MT-4 T-cell line to replication of an HIV-1 mutant lacking the gp41 cytoplasmic tail.
    J Virol 2020.

  32. Vrancken B, Zhao B, Li X, Han X, et al.
    COMPARATIVE CIRCULATION DYNAMICS OF THE FIVE MAIN HIV TYPES IN CHINA.
    J Virol 2020.

  33. Gottlieb GS, Rosenberg JM, Gonzalez RG, Gandhi RT, et al.
    Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance.
    N Engl J Med 2020;383:859-866.

  34. Patel F, Shiau S, Strehlau R, Shen Y, et al.
    Low Pretreatment Viral Loads in Infants With HIV in an Era of High-maternal Antiretroviral Therapy Coverage.
    Pediatr Infect Dis J 2020.

  35. Ahmed S, Cox C, Abrams E.
    COMMENTARY ON "SYMPTOM-BASED SCREENING IS NOT THE SOLUTION TO IMPROVE PEDIATRIC HIV TESTING".
    Pediatr Infect Dis J 2020.

  36. Tadesse BT, Foster BA, Latour E, Lim JY, et al.
    Predictors of Virologic Failure Among a Cohort of HIV-infected Children in Southern Ethiopia.
    Pediatr Infect Dis J 2020.

  37. Worobey M, Pekar J, Larsen BB, Nelson MI, et al.
    The emergence of SARS-CoV-2 in Europe and North America.
    Science 2020.

  38. Wang Y, Zhang Y, Tang T, Zhao W, et al.
    Natural killer cell counts in primary HIV infection predicts disease progression and immune restoration after treatment.
    Virology 2020;550:89-98.


Display articles in


Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:



Amedeo HIV Infection

Five-Week Literature

26 October 2020

19 October 2020

12 October 2020

05 October 2020

28 September 2020


21 September 2020

Multidisciplinary Journal Club

  1. Thomson MJ, Lok AS, Tapper EB.
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.

  2. Waterhouse DM, Garon EB, Chandler J, McCleod M, et al.
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131.

  3. Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, et al.
    Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Gastroenterology. 2020;159:481-491.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016